Enanta Pharmaceutica (ENTA) 29.37 $ENTA
Enanta Pharmaceuticals Announces HCV Data Presentations at The International Liver Congress(TM) 2016
BusinessWire - Wed Mar 30, 6:07AM CDT
--New data to be presented on AbbVie's investigational, pan-genotypic regimen consisting of ABT-493, Enanta's second protease inhibitor, in combination with ABT-530, AbbVie's NS5A inhibitor
ENTA: 29.37 (+0.81)
AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress(TM) 2016
PR Newswire - Wed Mar 30, 6:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International Liver Congress(TM) (ILC) 2016 in Barcelona, Spain, April 13-17, including real-world data that support clinical trial results seen in AbbVie's development program with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets). Abstracts presented will further expand scientific knowledge of VIEKIRAX and EXVIERA in genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infected patients, including those with compensated cirrhosis (Child-Pugh A).
ABBV: 57.12 (+0.12), ENTA: 29.37 (+0.81)
Forget Valeant, Buy These 5 Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Thu Mar 17, 9:10AM CDT
It's time to focus on drug stocks with interesting pipelines, good prospects and favorable Zacks Ranks.
SGYP: 2.76 (+0.04), VRX: 26.30 (-0.77), SCMP: 10.93 (+0.57), ARIA: 6.39 (+0.19), ENTA: 29.37 (+0.81), CORT: 4.68 (+0.41)
Enanta Pharmaceuticals to Present at the Barclays Global Healthcare Conference
BusinessWire - Thu Mar 10, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat format, or question and answer session with investors, at the Barclays Global Healthcare Conference on March 17, 2016 at 11:15 a.m. ET.
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals beats 1Q profit forecasts
Automated Insights - Mon Feb 08, 3:14PM CST
WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported fiscal first-quarter earnings of $26.2 million.
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
BusinessWire - Mon Feb 08, 3:02PM CST
--Royalty revenue for paritaprevir containing regimens was $17.9 million
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
BusinessWire - Mon Feb 01, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat format, or question and answer session with investors, at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016 at 9:15 a.m. ET.
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2015
BusinessWire - Thu Jan 28, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2015 after the U.S. markets close on February 8, 2016. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's research and development pipeline.
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Announces New R&D Initiatives in Hepatitis B Virus and Respiratory Syncytial Virus and Plan to Provide Data Updates on Programs in NASH and HCV at the 34th Annual J.P. Morgan Healthcare Conference
BusinessWire - Mon Jan 11, 7:00AM CST
--First subject dosed in phase 1 clinical study with cyclophilin inhibitor EDP-494 for hepatitis C virus infection
JPM: 59.22 (-0.49), ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Announces That AbbVie Has Initiated Enrollment of Six Global Phase 3 Clinical Studies of Its Once-Daily, Pan-Genotypic Hepatitis C Treatment
BusinessWire - Mon Jan 11, 6:10AM CST
--New investigational combination evaluates treatment durations of 12 weeks and as short as eight weeks in genotype 1 patients
ENTA: 29.37 (+0.81)
AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen
PR Newswire - Mon Jan 11, 6:00AM CST
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.
ABBV: 57.12 (+0.12), ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Announces the U.S. FDA Grants Priority Review to AbbVie's Supplemental New Drug Application for VIEKIRA PAK(R) Without Ribavirin in Genotype 1B Chronic Hepatitis C Virus Patients with Compensated Cirrhosis
BusinessWire - Thu Jan 07, 8:09AM CST
--TURQUOISE-III study showed 100 percent sustained virologic response at 12 weeks post-treatment (SVR12) in patients with genotype 1b (GT1b) chronic hepatitis C virus and compensated cirrhosis (Child-Pugh A)
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Announces HCV Data Presentations at The International Liver Congress(TM) 2016
BusinessWire - Wed Mar 30, 6:07AM CDT
--New data to be presented on AbbVie's investigational, pan-genotypic regimen consisting of ABT-493, Enanta's second protease inhibitor, in combination with ABT-530, AbbVie's NS5A inhibitor
ENTA: 29.37 (+0.81)
AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress(TM) 2016
PR Newswire - Wed Mar 30, 6:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International Liver Congress(TM) (ILC) 2016 in Barcelona, Spain, April 13-17, including real-world data that support clinical trial results seen in AbbVie's development program with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets). Abstracts presented will further expand scientific knowledge of VIEKIRAX and EXVIERA in genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infected patients, including those with compensated cirrhosis (Child-Pugh A).
ABBV: 57.12 (+0.12), ENTA: 29.37 (+0.81)
Forget Valeant, Buy These 5 Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Thu Mar 17, 9:10AM CDT
It's time to focus on drug stocks with interesting pipelines, good prospects and favorable Zacks Ranks.
SGYP: 2.76 (+0.04), VRX: 26.30 (-0.77), SCMP: 10.93 (+0.57), ARIA: 6.39 (+0.19), ENTA: 29.37 (+0.81), CORT: 4.68 (+0.41)
Enanta Pharmaceuticals to Present at the Barclays Global Healthcare Conference
BusinessWire - Thu Mar 10, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat format, or question and answer session with investors, at the Barclays Global Healthcare Conference on March 17, 2016 at 11:15 a.m. ET.
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals beats 1Q profit forecasts
Automated Insights - Mon Feb 08, 3:14PM CST
WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported fiscal first-quarter earnings of $26.2 million.
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
BusinessWire - Mon Feb 08, 3:02PM CST
--Royalty revenue for paritaprevir containing regimens was $17.9 million
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
BusinessWire - Mon Feb 01, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat format, or question and answer session with investors, at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016 at 9:15 a.m. ET.
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2015
BusinessWire - Thu Jan 28, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2015 after the U.S. markets close on February 8, 2016. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's research and development pipeline.
ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Announces New R&D Initiatives in Hepatitis B Virus and Respiratory Syncytial Virus and Plan to Provide Data Updates on Programs in NASH and HCV at the 34th Annual J.P. Morgan Healthcare Conference
BusinessWire - Mon Jan 11, 7:00AM CST
--First subject dosed in phase 1 clinical study with cyclophilin inhibitor EDP-494 for hepatitis C virus infection
JPM: 59.22 (-0.49), ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Announces That AbbVie Has Initiated Enrollment of Six Global Phase 3 Clinical Studies of Its Once-Daily, Pan-Genotypic Hepatitis C Treatment
BusinessWire - Mon Jan 11, 6:10AM CST
--New investigational combination evaluates treatment durations of 12 weeks and as short as eight weeks in genotype 1 patients
ENTA: 29.37 (+0.81)
AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen
PR Newswire - Mon Jan 11, 6:00AM CST
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.
ABBV: 57.12 (+0.12), ENTA: 29.37 (+0.81)
Enanta Pharmaceuticals Announces the U.S. FDA Grants Priority Review to AbbVie's Supplemental New Drug Application for VIEKIRA PAK(R) Without Ribavirin in Genotype 1B Chronic Hepatitis C Virus Patients with Compensated Cirrhosis
BusinessWire - Thu Jan 07, 8:09AM CST
--TURQUOISE-III study showed 100 percent sustained virologic response at 12 weeks post-treatment (SVR12) in patients with genotype 1b (GT1b) chronic hepatitis C virus and compensated cirrhosis (Child-Pugh A)
ENTA: 29.37 (+0.81)
